Celerion
and
BryanLGH Health System
, a locally owned, non-profit healthcare organization, announce an alliance to provide a dedicated wing at BryanLGH Medical Center West in Lincoln, Nebraska for early clinical studies including Phase I and First-In-Human.
This exclusive alliance will provide pharmaceutical, and biotechnology companies the opportunity to place clinical studies in a hospital environment, thus increasing safety for study volunteers and improving access to hospital procedures and techniques for studies placed at Celerion’s Lincoln clinical facility. Celerion will have access to 24 in-patient beds, in the newly launched Celerion-BryanLGH Clinical Research Unit. Celerion will leverage over forty years experience conducting clinical studies and will incorporate the same staff, global standard operating procedures and institutional review board, ensuring consistency across all studies executed at our sites.
“Improving safety for participants in clinical studies, while getting drugs to market faster, is critical to pharmaceutical companies”, said Philip Bach, Vice President, Clinical Research at Celerion. “This alliance will allow Celerion to conduct studies in a hospital environment, providing round-the-clock emergency care. Celerion will also strengthen their capabilities with access to state-of-the-art hospital techniques and equipment, such as chest X-rays, PET scans, and MRIs, for studies executed at our clinical facility in Lincoln, Nebraska.”
“We are very pleased to collaborate with Celerion on this venture. Celerion’s staff is among the best in the industry, with extensive experience and expertise – going back to its founding in Lincoln in 1933 as Harris Labs”, said Kimberly A. Russel, President and CEO at BryanLGH. “This alliance affirms a major commitment by BryanLGH Health System to clinical research and is a natural extension of our medical expertise. We will safely help get drugs to market faster, which will benefit everybody.”
BryanLGH is one of only 74 hospitals in the United States to have received both the
2010 Distinguished Hospital Award for Clinical Excellence™
and the
Patient Safety Excellent Award™
from HealthGrades®.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
The Rise of Predictive Engagement Tools in Clinical Trials
November 22nd 2024Patient attrition can be a significant barrier to the success of a randomized controlled trial (RCT). Today, with the help of AI-powered predictive engagement tools, clinical study managers are finding ways to proactively reduce attrition rates in RCTs, and increase the effectiveness of their trial. In this guide, we look at the role AI-powered patient engagement tools play in clinical research, from the problems they’re being used to solve to the areas and indications in which they’re being deployed.